Kristi Rosa

AE-related discontinuations of osimertinib were low, and no new treatment-related deaths were reported with the combination in EGFR-mutant NSCLC.

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.

Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.

Data from KEYNOTE-A18 support pembrolizumab plus concurrent chemoradiotherapy as a standard of care in this cervical cancer population.

Subgroup data from CARTITUDE-4 suggest that cilta-cel may overcome the poor prognosis associated with some high-risk features in multiple myeloma.

A post hoc analysis of NAPOLI-3 reveals clinical characteristics and treatment strategies associated with long-term survival in patients with metastatic PDAC treated with NALIRIFOX.

Treatment with KITE-363 yields no dose-limiting toxicities in a first-in-human phase 1 study.

PFS was improved with first-line sacituzumab govitecan plus pembrolizumab for patients with PD-L1–positive metastatic TNBC.

The phase 3 IMforte trial evaluating lurbinectedin plus atezolizumab is the first to show PFS and OS improvement with first-line maintenance for ES-SCLC.

Results from the phase 3 ENVISION trial suggest UGN-102 could be a non-surgical alternative to TURBT for recurrent low-grade intermediate-risk NMIBC.

Mirvetuximab soravtansine additionally showcased PFS, ORR, and DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Idecabtagene vicleucel led to high rates of MRD negativity in multiple myeloma who responded did not have complete responses to first-line therapy.

Data from the EV-302 trial support enfortumab vedotin plus pembrolizumab as a new standard of care in frontline urothelial cancer.

Updated CARTITUDE-4 trial data show cilta-cel induces deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Data from CheckMate-274 support adjuvant nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma.

A phase 2 study evaluated the efficacy of balstilimab and botensilimab in patients with MSS metastatic mCRC without liver metastases.

Cohort 5 of the ongoing phase 1/2 GOBLET study evaluated the safety of pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

An isatuximab-based quadruplet yields significant long-term benefits regardless of subsequent maintenance in in patients with transplant-eligible NDMM.

The phase 3 CamRelief study reported a pathologic complete response rate of 56.8% for camrelizumab plus chemo compared with 44.7% for chemo alone.

Elascestrant with abemaciclib elicited an overall response rate of 18% in ER+/HER2– Breast Cancer, results from the 2 trials show.

For patients with HMA–naive chronic myelomonocytic leukemia, an IO-202 combo demonstrated durable responses, a phase 1b study found.

For patients with HR–positive/HER2-negative breast cancer, neoadjuvant patritumab deruxtecan with or without letrozole showed antitumor activity.

Findings from DREAMM-7 support belantamab mafodotin plus bortezomib and dexamethasone as a standard of care in relapsed/refractory multiple myeloma.

For patients with relapsed or refractory diffuse large B-cell lymphoma in the US, tafasitamab elicited promising real-world efficacy outcomes.